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Introduction
Mycosis fungoides (MF) is a lymphoproliferative disor-
der involving neoplastic T lymphocytes. Infiltration of
neoplastic cells is invariably demonstrated in the skin.
Involvement of the lymph nodes, peripheral blood and vis-
cera is also often found. The histological features of MF
are characterised by marked epidermotropism of cytolog-
ically atypical T lymphocytes, with convoluted (cereberi-
form) nuclear contours. These cells form a band like infil-
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Mycosis fungoides (MF) is an indolent T cell lym-
phoma that is distinguished from other lymphomas
by its initial appearance on the skin. The histolog-
ic diagnosis of MF may be difficult because there is
significant overlap in the histologic features of
neoplastic T-cell infiltrates and inflammatory der-
matoses. This T-cell neoplasm commonly occurs in
a mixed, reactive background and can show only a
subtle degree of cytologic atypia, rendering histo-
logic diagnosis difficult. In this study MF consti-
tuted 0.86% of all non-Hodgkin’s lymphoma (NHL)
both T and B, as compared to the Western studies
which have reported 0.5% prevalence for MF of all
NHL. Polymerase chain reaction (PCR) technique
was used to assess T-cell clonality in paraffin-
embedded skin biopsies clinically and pathologi-
cally suspicious for early MF. Out of the 14 cases
diagnosed as MF, amplifiable DNA was isolated
from 6 cases, which were further studied for T-cell
receptor (TcR) – b, g, and d chain gene rearrange-
ments. Clonal product was seen in 4 out of 6 cases
for b, g, and d TcR chain genes. Association for
Epstein Barr virus (EBV) was observed in 3 out of 6
cases (50%) of MF. Although these 3 cases were pos-
itive for EBV by PCR, but were negative by in-situ
hybridization (ISH). No heterogeneity was noted in
these 3 cases of MF for BamHI E, K, N, and Z
regions of EBV. All six cases were negative for
HTLV-1 (tax region) by PCR. It was concluded that
the prevalence of MF in Pakistani population is
comparable to the Western data, and that EBV asso-
ciation to MF cases was higher than in Western
studies. (Pathology Oncology Research Vol 8, No 3,
194–199)
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trate in the upper papillary dermis and show formation of
Pautrier’s microabscesses in the epidermis. There is vari-
able admixture of histiocytes, eosinophils, and plasma
cells. Abnormal cells must be present in the epidermis to
make a definitive diagnosis of MF.1 It is estimated that in
the USA, MF develops in 1,000 new patients per year and
constitutes 0.5% of all NHLs.2 A clinical diagnosis of MF
in its early stages can be difficult and even on histological
examination at times is difficult to distinguish it from
benign inflammatory dermatoses such as lymphomatoid
drug reactions, contact dermatitis, lichen planus, spongi-
otic dermatitides, pityriasis lichenoides  et varioliformis
acuta, follicular mucinosis etc, particularly when mixed
cell populations with only occasional atypical cells are
observed. MF may produce practically all of the patterns
used for diagnosing inflammatory skin diseases.3 MF is
characterized immunohistochemically by the presence of
(CD 3+) T cell expressing a T-helper/inducer cell
immunophenotype (CD4+), with only rare cases having a
T-suppressor cell immunophenotype (CD8+).4 Break
points in chromosomes 1,9,14, and 17 and abnormalities
involving the gene for the TcR a (14q11) have been noted
frequently in patients with MF.5
Kanavaros et al6 and Peris et al7 have shown no signifi-
cant role for EBV in the development of cutaneous lym-
phoma. Whereas Dreno et al have reported 32% preva-
lence of EBV in cutaneous T-cell lymphomas.8 Several
studies have shown that nearly all patients with MF are
HTLV-1 seronegative, but by using polymerase chain reac-
tion (PCR) HTLV-1 DNA sequences has been detected in
peripheral blood mononuclear cells and cutaneous lesions
of some patients with MF.9 Other studies have shown no
role for HTLV-1 in the development of MF.10
The present study is the first to investigate the preva-
lence of MF, in a large tertiary care referral hospital receiv-
ing specimens from all over Pakistan, its association with




Specimens received in 10% neutral buffered formalin
were processed under standardized conditions for paraffin
embedding, cut at 5 mm thickness, and stained with hema-
toxylin and eosin (H & E).  Immunohistochemical analy-
sis was performed using CD45 (LCA), CD20 (L26),
CD45RO (UCHL1) and CD3 antibodies (Dako, Den-
mark). Antibody binding was detected by Vectastain (Vec-
tor Laboratories Inc, USA) following incubation with spe-
cific antibodies. Finally, the slides were counterstained
with Harris hematoxylin. Each assay included a negative
and a positive control comprising tonsilar tissues. 
PCR Amplification of b-globin, EBV and HTLV-1 Genome
DNA from 14 MF patient biopsies, 14 reactive lymph
nodes and 30 blood samples was extracted by Nucleon HT
kit (Biosciences, USA), according to the manufacturers
instruction. Reactive lymph node biopsies and blood sam-
ples were used as control for the presence of EBV and
HTLV-1. Purified DNA (500 ng) was added to a PCR mix
containing 0.2 mM deoxynucleotide triphosphates
(dNTPs), 1.5 mM MgCl2, 150 ng of each primer for b-glo-
bin and HTLV-1, 300 ng of each primer for EBV, 2.5U Taq
DNA polymerase (Advanced Biotechnologies, UK) in a
total volume of 50 µl. After initial denaturation at 94°C for
5 mins, 45 cycles of denaturation at 94°C for 1.5 min,
annealing 55°C (EBV and b-globin) or 58°C (HTLV-1) for
1.5 min and polymerization 72°C for 1.5 min were carried
out in an automated thermal cycler (Perkin Elmer 9600,
USA). The cycling program was ended with a final exten-
sion at 72°C for 7 minutes. PCR products of 240-bp for 
b-globin, 239-bp for EBV genome,11 and 159-bp for
HTLV-1 were seen.12
In Situ Hybridization (ISH)
Specimens positive for EBV by PCR were further
processed for the cellular localization of EBV genome
using in-situ hybridization (ISH) on fixed tissue sections.
Subsequently, tissue sections were hybridized with either
biotin labeled EBV, EBER-1 region specific probe or a
positive control probe13 prepared in 20% dextran sulphate
solution. A negative control slide was included with each
run. The target RNA and probe were denatured at 100C for
5 minutes and hybridized overnight. The hybridized probe
was detected using ISH detection system supplied by Life
Technologies, USA. 
Determination of variation in isolated EBV strains 
by PCR-SSCP
Heterogeneity in EBV DNA was identified using PCR-
SSCP as previously described by Dimitris et al with slight
modifications.14 The Bam HI E, N, K and Z regions of EBV
were examined for sequence variation. Primers, thermal
cycling and product analysis were as reported previously.15-
18 Briefly 5 µl of PCR product was mixed with 5 µl of gel
loading dye (95% formamide, 10 mM NaOH, 0.05% bro-
mophenol blue and 0.05% xylene cyanol) denatured at
95°C for 5 min, cooled on ice and applied immediately to
0.5X mutation detection enhancement (MDE) gel (FMC
BioProduct Rockland, USA). Electrophoresis was carried
out at room temperature in 0.6X TBE at 280 V. Gels were
stained with silver staining technique and photographed.
PCR Analysis of TcR b, g and d gene rearrangements
T-cell receptor (TcR) gene rearrangements were studied
using b, g and d chain primers for the V (variable), D (diver-
sity) and J (junctional) regions for T-cell respectively. Puri-
fied DNA (250 ng/µl) was added to PCR mix containing 0.2
mM dNTPs, 1.5 mM MgCl2, 68 pmoles of primers for b-
chain, 50 pmoles of primers for the g-chain, 30 pmoles of
primers for d-chain and 1.5 U Ampli Taq Gold. Primer
sequences, thermal cycling and product analysis were as
reported previously.19-23 Subsequently heteroduplex analysis
was performed exactly as described by Langerak et al.24
Results
In a period of 10 years between 1992 and 2001 a total of
1610 cases of NHL (both T and B) were diagnosed in the
Department of Pathology, The Aga Khan University Hos-
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pital, a major referral center in Pakistan. Cutaneous
involvement was present in 133 (8.26%), and 14 of such
cases (10.5%) were diagnosed as MF on the basis of mor-
phology, immunohistochemistry and where required by
TcR gene rearrangement studies. MF contributed 0.86% of
the total NHLs. The age ranged between 28 to 73 years
with a median age of 52.5 years and a male: female ratio
of 2.5:1. Four cases of MF presented as generalized body
lesions while the rest exhibited a discrete patch or plaque
over different body regions. 
Morphology, immunology and molecular characteristics
The cases were diagnosed on the basis of their histologi-
cal, immunological and molecular characteristics in accor-
dance with the REAL/WHO classification guidelines.25,26 By
immunohistochemistry all 14 cases expressed both T cell
markers i.e. UCHL-1 (Figure 1a,b) and CD3. These also
expressed LCA and were negative for CD20 marker. Out of
14 cases, amplifiable DNA was obtained from 6 cases,
which were further studied for TcR gene rearrangements. 
EBV and HTLV-1 DNA detection by PCR and ISH
The b-globin PCR was performed on all MF samples out
of which amplifiable DNA was obtained in 6 cases. The 
b-globin PCR positive samples were tested for the pres-
ence of EBV DNA and in 3 (50%) samples EBV PCR
product of 239-bp was detected. Whereas, no amplifiable
product was seen for the tax-region of HTLV-1. The EBV
PCR positive samples were also analyzed for the cellular
localization of EBV genome using ISH and were found to
be negative probably due to low copy number of EBV
genome in the cells. 
Polymorphism in Bam HI E, K, N, and Z regions 
by PCR-SSCP
The extent of hyper-variability in the Bam HI E, K, N
and Z regions of EBV was examined using PCR-SSCP
and none of them demonstrated diversity for these regions.
TcR Gene rearrangement
TcR clonality was seen in 4 out of 6 cases, where 2 cases
demonstrated both b, g TcR gene rearrangement, 1 case
showed g, b, d TcR gene rearrangement and in 1 case only
b chain gene rearrangement was seen (Figure 2a,b,c).
Discussion
Primary cutaneous lymphomas (NHL) represent a het-
erogenous group of NHLs, which shows considerable vari-
ation in clinical presentation, histology, immunophenotype
and prognosis. Approximately 25%-40% of NHLs occur in
extra nodal site, skin being the second most common site of
extranodal involvement after gastrointestinal tract.27 MF is
an indolent neoplasm of mature helper T lymphocytes that
manifests in skin in the form of patches, plaques, tumors or
erytheroderma, which may be present on the skin for years
and decades. In our study a total of 133 cases of NHLs both
B and T presenting as primary skin lesions were diagnosed
at AKUH over a span of 10 years (1992-2001). Out of these
133 cases, 14 (10.5%) were diagnosed as MF. In one of the
studies MF was diagnosed in adults and  the male:female
ratio was 2:1.2  Other study has shown that MF occurs in
middle aged adults with median age of 50 years and a M:F
ratio of 2.2:1.28 In our study the mean age of presentation
was 50 years, with a median of 52.5 and with the male:
female ratio of 2.5:1, which is quite comparable to the West-
ern studies. A study conducted in Tokyo has shown 20.8%
prevalence of MF among primary skin NHLs,29 whereas our
study showed 10.5%.
Out of 14 cases of MF, 4 cases (28.5%) presented as
generalized body rashes while the rest as discrete local-
ized patches and plaques. One patient presented with
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Figure 1a. Photomicrograph of HE stained section of the skin from
a patient with MF. Note dense dermal (D) infiltrate with focal epi-
dermotropism (E) by atypical lymphoid cells (Arrow). (20X).
E
D
generalized hyperpigmentation with no raised plaques or
tumors. Pigmentary changes in MF are not very rare,
although hypopigmented skin lesions are more often
reported in literature, there are few cases of MF present-
ing as hyperpigmented skin lesion.30 In our study only 1
patient out of 14 presented with flat hyperpigmented dif-
fuse lesion on the trunk. 
All MF casess in our study expressed LCA, both T-cell
markers i.e., UCHL1 and CD3  and none showed CD20 (a
B-cell marker) positivity. Histologically a clear distinction
between benign and malignant lymphocytic infiltrates is
not always easy. In fact at times it may be impossible to
make this distinction purely on morphological grounds. It
is precisely here where gene rearrangement studies may be
helpful. 
The ability to amplify specific regions of DNA from
paraffin-embedded tissue by PCR has a profound impact
on diagnostic pathology. In our study out of the 14 cases
DNA was amplified from 6 cases only. There could be
several reasons for the degradation of DNA for example
the fixative used, over fixation of tissue in formalin, autol-
ysis, and  presence of PCR inhibitors. 
Various studies have shown similarities between the skin
lesions of MF and Sezary syndrome (SS) and those of Adult
T-cell lymphoma/leukemia (ATLL), which is related to
HTLV-1. This prompted consideration for a retrovirus role
in CTCL. Several studies have shown that nearly all
patients with MF are HTLV-1 seronegative, but using PCR,
HTLV-1 DNA sequences has been detected in peripheral
blood mononuclear cells and cutaneous lesions of some
patients with MF.9 Other studies have shown no role for
HTLV-1 in the development of MF.10 In our study no associ-
ation between MF and HTLV-1 was observed by PCR.
EBV is a human herpesvirus that infects B-lymphocytes
and certain epithelial cells in the oropharynx. It has been
frequently identified in cases of nasopharyngeal carcino-
ma, endemic Burkitt’s lymphoma, a subset of cases of
Hodgkin’s lymphoma and lymphomas developing in the
setting of immunosuppression and immunodeficiency.31,32
Angel et al33, have shown no significant association of
EBV in 28 cases of primary cutaneous T-cell lymphoma
originating from UK. Whereas reports by Dreno et al 8
have shown 32% association of this virus with cutaneous
T cell lymphomas, Mouly et al 34 have shown pathogenic
role of this virus with cutaneous T-cell lymphoma . Simi-
larly our study has shown association of EBV in 50%
cases of MF. All the control samples including reactive
lymph nodes and blood samples were negative for the
presence of EBV and HTLV-1. Seroprevalence of HTLV-1
in general population was not studied.
Since EBV-infected lymphoid cells and tissues do not
exhibit specific morphologic changes, a definitive identifi-
cation of the virus in tissues requires detection of EBV
DNA/RNA or gene products using specialized techniques
such as ISH. In our study EBV RNA was not detected by
ISH in EBV positive cases by PCR. Similarly a study con-
ducted by Anagnostopolus et al35 showed presence of EBV
in 15 out of 76 cutaneous T-cell lymphomas cases by PCR
but with ISH only 7 cases out of 15 showed presence of
EBV. Hence above mentioned study and ours indicate that
there is a discrepancy between the results obtained by PCR
and ISH and is apparently caused by the low copy number
of infected cells per tissue section. EBV can be differenti-
ated according to size polymorphism depending on the
number of internal repeats in the Bam HI E, K, N, and Z
regions. We have studied sequence polymorphism in EBV
positive cases of MF using SSCP assay in potential hyper-
variable domains of EBV of Bam HI E, K, N, and Z
regions in tissue of MF patients. No polymorphism was
seen in any of the regions. It is possible that hypervariable
loci within the EBV genome are located in Bam HI for
other regions that were not performed in this study.
Whereas Dimitris et al14 have shown hyper variability in
Bam HI K and N segments indicating infection by multi-
ple variants of EBV in lymphoid cell lines, tissues, and
body fluids.
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Figure 1b. Serial section from the same lesion stained with a




The T-cell receptor chain gene rearrangements in lym-
phomas serve as a specific marker for each tumor and
detection of such gene rearrangements may enhance the
identification of persistent tumor. Molecular analysis of
TcR genes is frequently used to prove or exclude clonality
and thereby support the diagnosis of suspected T cell pro-
liferations. PCR-based clonality assessment should
include analyses that discern between PCR products
derived from monoclonal and polyclonal cell populations.
One such method is heteroduplex analysis. After denatu-
ration/renaturation, PCR products of clonality rearranged
TcR genes give rise to homoduplexes (specific clonal
band), whereas in case of polyclonal cells heteroduplexes
with heterogeneous junctions are formed (smear). 
Ashton et al performed TcR g-chain gene rearrangement
on 27 formalin fixed, paraffin-embedded, clinically and
histologically diagnosed MF cases and found clonal prod-
uct for g-chain in 16 of 27 (59%) cases.36 Similarly, study
conducted by Toro et al on 3 cutaneous T cell lymphoma
(CTCL) cases, showed clonal T-cell receptor g, d chain
gene rearrangement in all 3 cases37 having no association
with EBV. Whereas in our study we have seen g, d TcR
chain gene rearrangement in one case with presence of
EBV. Straten et al studied TcR b-chain gene rearrangement
in 24 CTCL cases comprising of 7 cases of MF, 4 of SS, 3
of lymphomatoid papulosis and 3 of large cell CTCL with
CD30 expression and 7 without CD30 expression. Clonal
product was seen for b-chain in 18 patients, whereas in
remaining 6 no clonal product was seen.38 In our study out
of the 6 cases clonal product was seen for TcR b, g, and d
chain genes in 4 cases out which 3 cases showed EBV
presence. The remaining 2 cases showed polyclonal smear
suggesting that b, g chain gene rearrangement is also com-
mon among MF patients in our population. Besides this,
we have also seen TcR d-chain gene rearrangement in 1
patient (Figure 2a,b,c). In addition, this study further
affirms that the detection of rearranged T-cell receptor
genes can be a sensitive and practical method for the diag-
nosis and characterization of T-cell neoplasm. 
Hence we conclude prevalence of MF in Pakistani popu-
lation is comparable to Western studies, higher frequency of
EBV may contribute to the pathogenesis of the disease and
g, b TcR clonal gene rearrangements are common in MF.
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